Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALXN1840 Copper Balance Study in Wilson Disease
NCT04573309Phase 2Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Sep 2020
- Primary completion
- Jun 2022
- Modality
- Classical Binding Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of atn-224 in Wilson disease (WD), sponsored by Alexion Pharmaceuticals. Started Sep 2020; status: completed.
02
Drugs
atn-224
03
Conditions
Wilson disease (WD)
Beyond the preview
Go deeper on NCT04573309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04573309.